These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 16278406

  • 1. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
    Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH.
    Clin Cancer Res; 2005 Nov 01; 11(21):7834-40. PubMed ID: 16278406
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
    Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB.
    Cancer Chemother Pharmacol; 2009 Apr 01; 63(5):903-10. PubMed ID: 18682950
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
    Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T, Cruff D, Chauhan B, Iannitti D, Harrington D, Safran H.
    Am J Clin Oncol; 2006 Aug 01; 29(4):376-9. PubMed ID: 16891865
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR.
    Clin Cancer Res; 2008 Sep 15; 14(18):5856-63. PubMed ID: 18794097
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
    Singer JW.
    J Control Release; 2005 Dec 05; 109(1-3):120-6. PubMed ID: 16297482
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ.
    Clin Cancer Res; 2004 Jun 01; 10(11):3708-16. PubMed ID: 15173077
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
    Soepenberg O, Sparreboom A, de Jonge MJ, Planting AS, de Heus G, Loos WJ, Hartman CM, Bowden C, Verweij J.
    Eur J Cancer; 2004 Mar 01; 40(5):681-8. PubMed ID: 15010068
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
    Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD.
    J Clin Oncol; 2005 Nov 01; 23(31):7785-93. PubMed ID: 16258082
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 13. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
    Berkenblit A, Eder JP, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):584-90. PubMed ID: 17255281
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW.
    Clin Cancer Res; 2005 Nov 01; 11(21):7866-71. PubMed ID: 16278410
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.
    Clin Cancer Res; 2002 May 01; 8(5):1038-44. PubMed ID: 12006516
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
    Armstrong DK, Fleming GF, Markman M, Bailey HH.
    Gynecol Oncol; 2006 Nov 01; 103(2):391-6. PubMed ID: 16626792
    [Abstract] [Full Text] [Related]

  • 20. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.